Iguratimod as Treatment for Refractory Lupus Nephritis

Summary

This study is to evaluate the efficacy and safety of a novel chemical synthetic agent iguratimod as treatment of refractory lupus nephritis. All subjects should have at least one failed immunosuppressive treatment and suffer active nephritis at the screening stage. The study period is 52 week. All the subject will receive therapy of iguratimod combined with steroids.

Timeline

Start

2017-05-08

Primary completion

2018-05-08

Completion

2019-04-30

Drugs

Indications